Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44] (S0959804917300850) (10.1016/j.ejca.2017.01.024));Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

European Journal of Cancer

Volumn 76, Issue , 2017, Pages 36-44

  Massard, Christophe ^a   Chi, Kim Nguyen ^b   Castellano, Daniel ^c   de Bono, Johann ^d   Gravis, Gwenaelle ^e   Dirix, Luc ^f   Machiels, Jean Pascal ^g   Mita, Alain ^h   Gonzalez, Begona Mellado ⁱ   Turri, Sabine ^j   Maier, Joan ^k   Csonka, Denes ^k   Chakravartty, Arunava ^l   Fizazi, Karim ^m  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e INSTITUT PAOLI CALMETTES   (France)

^f SINT AUGUSTINUS HOSPITAL   (Belgium)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j NOVARTIS PHARMA K K   (Japan)

^k NOVARTIS PHARMA AG   (Switzerland)

^l NOVARTIS HEALTHCARE PVT LTD   (India)

^m UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

Abiraterone acetate (AA); Buparlisib (BKM120); Castration resistant prostate cancer (CRPC); Dactolisib (BEZ235)

Indexed keywords

ABIRATERONE ACETATE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BUPARLISIB; DACTOLISIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; MORPHOLINE DERIVATIVE; NVP-BKM120; QUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; ATRIAL FIBRILLATION; BACKACHE; BODY WEIGHT DISORDER; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CAUCASIAN; CHILL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; EPISTAXIS; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; FEVER; GASTROESOPHAGEAL REFLUX; HEADACHE; HICCUP; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPOKALEMIA; HYPOPHOSPHATEMIA; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; LACRIMATION DISORDER; LIMB PAIN; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NECK PAIN; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRESYNCOPE; PRIORITY JOURNAL; PROSTATE CANCER WORKING GROUP 2 CRITERIA; PRURITUS; RASH; RECOMMENDED DRUG DOSE; RECTUM HEMORRHAGE; SIDE EFFECT; SOMNOLENCE; SPINAL CORD COMPRESSION; STOMATITIS; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; UROGENITAL TRACT DISEASE ASSESSMENT; VERTIGO; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VERY ELDERLY;

ABIRATERONE ACETATE; AGED; AGED, 80 AND OVER; AMINOPYRIDINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; ASTHENIA; CHILLS; DIARRHEA; FEVER; HUMANS; HYPERGLYCEMIA; IMIDAZOLES; KALLIKREINS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORPHOLINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUINOLINES; STOMATITIS; VOMITING;

EID: 85016833054     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.05.003     Document Type: Erratum

References (20)

1. [1] Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26 (2015), 1589–1604.
2. [2] Massard, C., Fizazi, K., Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 17 (2011), 3876–3883.
3. [3] Reid, A.H., Attard, G., Ambroisine, L., Fisher, G., Kovacs, G., Brewer, D., et al., Transatlantic Prostate Group. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102 (2010), 678–684.
4. [4] Yap, T.A., Zivi, A., Omlin, A., de Bono, J.S., The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 8 (2011), 597–610.
5. [5] Ang, J.E., Olmos, D., de Bono, J.S., CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 100 (2009), 671–675.
6. [6] Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18 (2010), 11–22.
7. [7] Robinson, D., Van Allen, E.M., Wu, Y.M., Schultz, N., Lonigro, R.J., Mosquera, J.M., et al. Integrative clinical genomics of advanced prostate cancer. Cell 161 (2015), 1215–1228 Erratum in: Cell 2015;162:454.
8. [8] Gao, H., Ouyang, X., Banach-Petrosky, W.A., Shen, M.M., Abate-Shen, C., Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res 66 (2006), 7929–7933.
9. [9] Carver, B.S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19 (2011), 575–586.
10. [10] Bendell, J.C., Rodon, J., Burris, H.A., Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30 (2012), 282–290.
11. [11] Burris, H., Rodon, J., Sharma, S., Herbst, R.S., Tabernero, J., Infante, J.R., et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients with advanced solid tumors. J Clin Oncol, 28, 2010 (suppl; abstr 3005):15s [Abstract].
12. [12] de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., et al., COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 (2011), 1995–2005.
13. [13] Fizazi, K., Scher, H.I., Molina, A., Logothetis, C.J., Chi, K.N., Jones, R.J., et al., COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13 (2012), 983–992 Erratum in: Lancet Oncol 2012;13:e464. Lancet Oncol 2014;15:e365.
14. [14] Ryan, C.J., Smith, M.R., de Bono, J.S., Molina, A., Logothetis, C.J., de Souza, P., et al., COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 (2013), 138–148 Erratum in: N Engl J Med 2013;368:584.
15. [15] Fitzpatrick, J.M., Bellmunt, J., Fizazi, K., Heidenreich, A., Sternberg, C.N., Tombal, B., et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 50 (2014), 1617–1627.
16. [16] Horwich, A., Hugosson, J., de Reijke, T., Wiegel, T., Fizazi, K., Kataja, V., Panel Members – European Society for Medical Oncology. Prostate cancer: ESMO consensus conference guidelines 2012. Ann Oncol 24 (2013), 1141–1162.
17. [17] Ham, W.S., Cho, N.H., Kim, W.T., Ju, H.J., Lee, J.S., Choi, Y.D., Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy. J Urol 182 (2009), 1378–1384.
18. [18] Sarker, D., Reid, A.H., Yap, T.A., de Bono, J.S., Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15 (2009), 4799–4805.
19. [19] Templeton, A.J., Dutoit, V., Cathomas, R., Rothermundt, C., Bärtschi, D., Dröge, C., et al., Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 64 (2013), 150–158.
20. [20] de Bono, J.S., De Giorgi, U., Massard, C., Bracarda, S., Nava Rodrigues, D., Kocak, I., et al. PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol 27:Suppl. 6 (2016), vi243–vi265 (Abstract 718O).